AOBiome Therapeutics, Inc.
Created in 2013
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
1,431 2,419Activities
Technologies
Entity types
Location
125 Cambridgepark Dr #5th, Cambridge, MA 02140, USA
Cambridge
United States of America
Employees
Scale: 2-10
Estimated: 16
Engaged corporates
1
0 0Added in Motherbase
5 years, 2 months ago
biotech Value proposition
AOBiome is focused on transforming human health by developing microbiome-based therapies for inflammatory conditions.
AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic inflammatory conditions. Founded in 2012 by PatientsLikeMe founder Jamie Heywood and MIT-trained Chemical Engineer David Whitlock, AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. The company's portfolio includes multiple clinical-stage programs: a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2a study to treat patients with adult eczema (atopic dermatitis), a Phase 2 study for the prevention of episodic migraines, and a Phase 1b/2a clinical trial for the treatment of allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications.
Home - AOBiome
AOBiome is a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other diseases. Our proprietary product candidates harness a strain of class-defining, auto-regulating Ammonia Oxidizing Bacteria, or AOB, a human commensal with well-understood and well-characterized biochemical properties that are critical to human health. We believe that the application of AOB has the potential to restore critical biological and biochemical processes through the symbiotic relationship between humans and this naturally-existing bacteria to address significant clinical need at various stages of disease. We have six ongoing clinical programs in acne vulgaris, or acne, atopic dermatitis, or eczema, rosacea, allergic rhinitis, migraine and hypertension, and multiple ongoing preclinical programs, including ones addressing pulmonary and gastrointestinal disorders.
https://www.aobiome.com/
